51 related articles for article (PubMed ID: 9303513)
1. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.
Shiffman ML; Hofmann CM; Thompson EB; Ferreira-Gonzalez A; Contos MJ; Koshy A; Luketic VA; Sanyal AJ; Mills AS; Garrett CT
Hepatology; 1997 Sep; 26(3):780-5. PubMed ID: 9303513
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for beneficial response to interferon-alfa therapy in chronic hepatitis C.
Yoon SK; Kim SS; Park YM; Shim KS; Lee CD; Sun HS; Park DH; Kim BS; Ryu WS; Cho JM
Korean J Intern Med; 1995 Jul; 10(2):94-102. PubMed ID: 7495780
[TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C.
Larrea E; Garcia N; Qian C; Civeira MP; Prieto J
Hepatology; 1996 Feb; 23(2):210-7. PubMed ID: 8591843
[TBL] [Abstract][Full Text] [Related]
4. Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.
Tada T; Kumada T; Okushin H; Tani J; Takaguchi K; Tsutsui A; Toyoda H; Yasuda S; Dohmen K; Hiraoka A; Michitaka K; Nouso K; Kariyama K; Kim SR; Kim SK; Fujioka S; Mikami S; Watanabe Y; Tamai T; Atsukawa M; Itokawa N; Tanaka H; Tsuji K; Ishikawa T; Imai M; Itobayashi E; Shibata H; Shimada N
Infect Dis Ther; 2021 Mar; 10(1):269-280. PubMed ID: 33141401
[TBL] [Abstract][Full Text] [Related]
5. The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.
Mizuno K; Toyoda H; Yasuda S; Tada T; Kumada T; Sone Y; Tanaka J
J Gastroenterol; 2019 Sep; 54(9):829-836. PubMed ID: 31161311
[TBL] [Abstract][Full Text] [Related]
6. Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan.
Toyoda H; Atsukawa M; Uojima H; Nozaki A; Tamai H; Takaguchi K; Fujioka S; Nakamuta M; Tada T; Yasuda S; Chuma M; Senoh T; Tsutsui A; Yamashita N; Hiraoka A; Michitaka K; Shima T; Akahane T; Itobayashi E; Watanabe T; Ikeda H; Iio E; Fukunishi S; Asano T; Tachi Y; Ikegami T; Tsuji K; Abe H; Kato K; Mikami S; Okubo H; Shimada N; Ishikawa T; Matsumoto Y; Itokawa N; Arai T; Tsubota A; Iwakiri K; Tanaka Y; Kumada T
Open Forum Infect Dis; 2019 May; 6(5):ofz185. PubMed ID: 31123693
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma after direct-acting antiviral therapy for chronic HCV infection: Is it a real risk?
Dias C; Duarte-Ribeiro F; Pipa S; Barbosa AR; Mota M; Rosas Vieira F
IDCases; 2018; 14():e00450. PubMed ID: 30191133
[TBL] [Abstract][Full Text] [Related]
8. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Toyoda H; Atsukawa M; Takaguchi K; Senoh T; Michitaka K; Hiraoka A; Fujioka S; Kondo C; Okubo T; Uojima H; Tada T; Yoneyama H; Watanabe T; Asano T; Ishikawa T; Tamai H; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Deguchi A; Itobayashi E; Mikami S; Moriya A; Okubo H; Tani J; Tsubota A; Tanaka Y; Masaki T; Iwakiri K; Kumada T
J Gastroenterol; 2018 Dec; 53(12):1276-1284. PubMed ID: 29740665
[TBL] [Abstract][Full Text] [Related]
9. Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.
Cozen ML; Ryan JC; Shen H; Cheung R; Kaplan DE; Pocha C; Brau N; Aytaman A; Schmidt WN; Pedrosa M; Anand BS; Chang KM; Morgan T; Monto A
Dig Dis Sci; 2016 Jun; 61(6):1744-56. PubMed ID: 27059981
[TBL] [Abstract][Full Text] [Related]
10. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus.
Tachi Y; Hirai T; Toyoda H; Tada T; Hayashi K; Honda T; Ishigami M; Goto H; Kumada T
PLoS One; 2015; 10(7):e0133515. PubMed ID: 26214180
[TBL] [Abstract][Full Text] [Related]
11. Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.
Yang Z; Zhuang L; Lu Y; Xu Q; Chen X
Biomed Res Int; 2014; 2014():941085. PubMed ID: 25247194
[TBL] [Abstract][Full Text] [Related]
12. Nonresponse to interferon-α based treatment for chronic hepatitis C infection is associated with increased hazard of cirrhosis.
Cozen ML; Ryan JC; Shen H; Lerrigo R; Yee RM; Sheen E; Wu R; Monto A
PLoS One; 2013; 8(4):e61568. PubMed ID: 23637856
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy.
Martinez SM; Foucher J; Combis JM; Métivier S; Brunetto M; Capron D; Bourlière M; Bronowicki JP; Dao T; Maynard-Muet M; Lucidarme D; Merrouche W; Forns X; de Lédinghen V
PLoS One; 2012; 7(10):e47715. PubMed ID: 23082200
[TBL] [Abstract][Full Text] [Related]
14. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.
Fried MW; Navarro VJ; Afdhal N; Belle SH; Wahed AS; Hawke RL; Doo E; Meyers CM; Reddy KR;
JAMA; 2012 Jul; 308(3):274-82. PubMed ID: 22797645
[TBL] [Abstract][Full Text] [Related]
15. Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C.
Reddy KR; Belle SH; Fried MW; Afdhal N; Navarro VJ; Hawke RL; Wahed AS; Doo E; Meyers CM;
Clin Trials; 2012 Feb; 9(1):102-12. PubMed ID: 22058086
[TBL] [Abstract][Full Text] [Related]
16. Dialysis reduces portal pressure in patients with chronic hepatitis C.
Khurana S; Simcox T; Twaddell W; Drachenberg C; Flasar M
Artif Organs; 2010 Jul; 34(7):570-9. PubMed ID: 20653650
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C Virus Therapy-related Skin Manifestations.
Fortune BE; Francis S; Forman LM
Gastroenterol Hepatol (N Y); 2010 May; 6(5):326-8. PubMed ID: 20567589
[No Abstract] [Full Text] [Related]
18. The management of patients awaiting liver transplantation.
Li KK; Neuberger J
Nat Rev Gastroenterol Hepatol; 2009 Nov; 6(11):648-59. PubMed ID: 19881517
[TBL] [Abstract][Full Text] [Related]
19. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C virus infection--pathobiology and implications for new therapeutic options.
Davis GL; Krawczynski K; Szabo G
Dig Dis Sci; 2007 Apr; 52(4):857-75. PubMed ID: 17333350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
